AM-Pharma Holding BV

43 articles about AM-Pharma Holding BV

• AM-Pharma Provides Business Update and Outcome of Pre-planned Interim Futility Analysis of Phase 3 REVIVAL Study

  10/20/2022

  AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, provided a business update and the outcome from its pre-planned 400-patient interim futility analysis for the pivotal phase 3 REVIVAL study, which has been stopped for futility based on the study’s primary endpoint.

• AM-Pharma Announces Publication of In Vivo Acute Kidney Injury Study Demonstrating Ilofotase Alfa’s Dual Protective Mechanism

  7/5/2022

  AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced new data indicating that ilofotase alfa protects against ischemia-reperfusion induced acute kidney injury (AKI) has been published in the journal, Frontiers in Medicine-Nephrology.

• AM-Pharma to Participate in Upcoming Jefferies Healthcare Conference

  6/6/2022

  AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced that Lars Boesgaard, Chief Financial Officer, is scheduled to present at the Jefferies Healthcare Conference, being held in New York, NY on Wednesday, June 8th , 2022 at 8:00 AM ET.

• 400 Patients Have Been Enrolled in AM-Pharma’s Pivotal Phase 3 Study of Ilofotase Alfa for the Treatment of Sepsis-associated Acute Kidney Injury

  4/25/2022

  AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced that 400 patients have now been enrolled in the main trial population in the pivotal Phase 3 REVIVAL study.

• AM-Pharma to Participate in SVB Leerink Biopharma Private Company Connect

  3/22/2022

  AM-Pharma’s purpose is to save and improve the lives of patients confronted with severe medical conditions.

• AM-Pharma Announces Two Presentations at the 27th International Conference on Advances in Critical Care Nephrology

  3/7/2022

  AM-Pharma B.V. today announced two presentations at the 27th International Conference on Advances in Critical Care Nephrology in San Diego, CA.

• AM-Pharma to Participate in Upcoming Investor and Scientific Conferences

  3/2/2022

  AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, announced that members of its senior management team are scheduled to participate in the following investor conferences.

• AM Pharma to Participate in Upcoming Investor Conferences - Jan 05, 2022

  1/5/2022

  AM Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, announced that Erik van den Berg, the Company’s Chief Executive Officer, and Lars Boesgaard, Chief Financial Officer, will participate in the following investor conferences.

• AM-Pharma Appoints Lars Boesgaard as Chief Financial Officer and Establishes U.S. Affiliate AM-Pharma Inc.

  9/15/2021

  AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, announced the appointment of Lars R. Boesgaard as Chief Financial Officer, effective immediately.

• AM-Pharma and Kyowa Kirin Sign Exclusive License Agreement for Commercialization of Ilofotase Alfa in Japan

  9/8/2021

  AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, and Kyowa Kirin Co., Ltd., a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies, announced that they have entered into an exclusive license agreement under which Kyowa Kirin gains the rights to develop and commercialize ilofotase alfa, AM-Pharma’s proprietary recombinant human alkaline phosphatase.

• AM-Pharma Appoints Mark Altmeyer as Chairman of its Supervisory Board

  7/6/2021

  AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, announced the appointment of Mark Altmeyer, MBA, as Chairman of its Supervisory Board.

• AM-Pharma Enrolls First Patient in Japan for Ongoing Phase III SA-AKI Pivotal REVIVAL Trial

  7/1/2021

  AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, announced the enrollment of the first patient in Japan as part of its ongoing global pivotal Phase III trial, called REVIVAL.

• AM-Pharma Appoints Martijn Negen as VP Commercial Strategy

  6/15/2021

  AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, announced the appointment of Martijn Negen, MSc, MBA, as Vice President for Commercial Strategy.

• 

  BioSpace Global Roundup: Cevec Licenses AAV Program to Biogen

  1/14/2021

  Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.

• AM-Pharma Announces Enrollment and Financing of COVID-19 Cohort in Phase III REVIVAL Trial

  1/7/2021

  RVO, an agency of the Dutch Ministry of Economic Affairs and Climate Policy, provides a loan of up to €5 million for the COVID-19 cohort clinical study

• AM-Pharma Announces Enrollment of the First Patient in REVIVAL Phase III Pivotal Trial in Patients with Sepsis-Associated Acute Kidney Injury

  11/12/2020

  Trial to confirm potential of AM-Pharma’s recombinant alkaline phosphatase to reduce mortality, as demonstrated in the Phase II STOP-AKI study

• AM-Pharma Appoints Chief Medical Officer and VP Manufacturing to Support Global Pivotal Trial in Sepsis-associated Acute Kidney Injury

  10/20/2020

  AM-Pharma B.V., an emerging leader focused on the treatment of kidney disease, sepsis and organ injury, announced the appointment of Maarten Kraan, M.D., Ph.D., as Chief Medical Officer and Teun van de Laar, Ph.D., as Vice President Manufacturing and Supply Chain Management.

• AM-Pharma Announces the Appointment of Rita Jain M.D. to its Supervisory Board

  7/1/2020

  AM-Pharma B.V., an emerging leader focused on the treatment of acute kidney injury, announced the appointment of Rita Jain, M.D., to the Company’s Supervisory Board.

• AM-Pharma Adds Regulatory, Business Development and Legal Expertise to Leadership Team

  6/29/2020

  AM-Pharma B.V., an emerging leader focused on the treatment of acute kidney injury, announced the appointment of Wolfgang Meder, Ph.D., as Vice President, Regulatory Affairs and Quality Management, and Laetitia Szaller as General Counsel & Vice President, Business Development.

• AM-Pharma Increases Funding to €163m for Phase-III Trial of recAP in SA-AKI

  3/31/2020

  AM-Pharma B.V., a clinical stage biopharmaceutical company leading in the development of a treatment for acute kidney injury with its innovative recombinant human Alkaline Phosphatase therapeutic, announces that it has raised additional funds of €47m [US$52m], increasing the total recent fundraising to €163m [US$176m].